Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients

NCT03127631 · View on ClinicalTrials.gov ↗

Study Summary

RADICAL PC1 is a prospective cohort study of men with a new diagnosis of prostate cancer. RADICAL PC2 is a randomized, controlled trial of a systematic approach to modifying cardiovascular and lifestyle risk factors in men with a new diagnosis of prostate cancer.

Interventions

  • BEHAVIORAL Exercise
  • BEHAVIORAL Nutrition
  • BEHAVIORAL Smoking cessation
  • DRUG Statin (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin)
  • DRUG ACE inhibitor

Study Locations (20)

Rio Grande do Sul

  • Hospital de Caridade de Ijuí — Ijuí
  • Hospital de Clínicas de Porto Alegre — Porto Alegre
  • Irmandade Da Santa Casa De Misericórdia De Porto Alegre — Porto Alegre
  • Hospital Mae de Deus — Porto Alegre

Paraná

  • Sociedade Hospitalar Angelina Caron — Campina Grande do Sul
  • Nucleo de Pesquisa Clinica Hospital do Rocio — Campo Largo
  • Centro Médico São Francisco — Curitiba

São Paulo

  • Hospital Municipal de Barueri — Barueri
  • Faculdade de Medicina da Universidade Estadual Paulista - Campus de Botucatu - UNESP — Botucatu
  • Hospital Universitário São Francisco na Providência de Deus — Bragança Paulista

South Australia

  • Royal Adelaide Hospital — Adelaide
  • Flinders Medical Center — Adelaide

Minas Gerais

  • Hospital Felício Rocho — Belo Horizonte
  • Universidade Federal do Triângulo Mineiro — Uberaba

Georgia

  • Georgia Cancer Center at Augusta University — Augusta

Kansas

  • University of Kansas Medical Center — Kansas City

New South Wales

  • Westmead Hospital — Westmead

Trial Details

FieldValue
Enrollment Target 6,000 participants
Start Date 2015-10-21
Est. Completion 2026-12
Phase NA

Sponsor

McMaster University

13 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03127631

The ClinicalTrials.gov registry entry for NCT03127631 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 6,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is McMaster University, which has 13 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 5 interventions — of which Exercise is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT03127631 reports 20 study locations spanning 11 distinct geographic areas — top geographies include Rio Grande do Sul, Paraná, São Paulo. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT03127631 about?

NCT03127631 is a clinical study titled "A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients". RADICAL PC1 is a prospective cohort study of men with a new diagnosis of prostate cancer. RADICAL PC2 is a randomized, controlled trial of a systematic approach to modifying cardiovascular and lifestyle risk factors in men with a new diagnosis of prostate cancer.

What is the current status of trial NCT03127631?

This trial is currently recruiting. It is a NA study. The enrollment target is 6,000 participants. The study started on 2015-10-21. Estimated completion is 2026-12.

What conditions does trial NCT03127631 study?

This clinical trial studies the following conditions: Prostate Cancer, Cardiovascular Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT03127631?

The interventions under investigation include: Exercise (BEHAVIORAL), Nutrition (BEHAVIORAL), Smoking cessation (BEHAVIORAL), Statin (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin) (DRUG), ACE inhibitor (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT03127631?

This trial is sponsored by McMaster University, which has 13 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT03127631 being conducted?

This trial has 20 study locations across Georgia, Kansas, New South Wales, South Australia, Federal District. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial